Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cyclopharm Limited ( (AU:CYC) ) has shared an update.
Cyclopharm Limited reported record operating revenue of $32.3 million for the year ended 31 December 2025, a 17% increase on 2024, driven by strong growth in its Technegas® business and third-party distribution activities. Despite the higher revenue and a cash balance of $6.6 million at year-end, the company remained loss-making, with a net loss after tax of $17.2 million, although the loss widened in line with revenue as it scaled its operations.
Technegas® revenue rose 10% to $16.7 million, underpinned by rapid expansion in the U.S., where Technegas® sales jumped 226% to $2.7 million and the country became Cyclopharm’s largest single market. Third-party distribution revenue climbed 26% to $15.6 million on robust consumables and service demand, while more than 150 Technegas® generators have now been landed in the U.S. and are available for deployment, positioning the company for further growth but with no dividend declared as it continues to invest.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is a specialist medical technology company focused on nuclear medicine imaging. Its primary product is the Technegas® system, used for functional lung imaging, with an increasing market focus on the United States, which has become the company’s largest individual market. The group also generates significant third-party distribution revenue from consumables and services.
Average Trading Volume: 78,626
Technical Sentiment Signal: Sell
Current Market Cap: A$106.1M
See more data about CYC stock on TipRanks’ Stock Analysis page.